54.32
2.60%
-1.45
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious - Benzinga
BMS Delivers Q3 Beat, Raises 2024 Guidance Amid Strong Demand for Legacy and Newer Drugs - BioSpace
Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
A promising schizophrenia drug showed mixed results. What does that mean for patients?WGN Radio - WGN Radio - Chicago
December 13th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript - The Motley Fool
Bristol Myers earnings beat expectations, driven by sales of older drugs - Reuters
Bristol Myers earnings beat expectations, driven by sales of older drugs By Reuters - Investing.com
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 - BioSpace
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View - Nasdaq
Bristol Myers Squibb stock rises, Merck moves lower. Here's why. - Yahoo Finance
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit - Benzinga
Bristol Myers Q3 earnings beat expectations, helped by sales of older drugs - PharmaLive
Bristol Myers’s stock pops as earnings top estimates and company raises guidance - MarketWatch
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Bristol-Myers hikes annual earnings guidance as Q3 exceeds expectations; shares up - MSN
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings: Revenue Surpasses Estimates at $11.9 Billion, GAAP EPS at $0.60 - GuruFocus.com
Bristol Myers Squibb's Earnings Surpass Expectations With Strong Drug Sales - Finimize
Bristol-Myers raises outlook ahead of consensus after Q3 beat - MSN
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Bristol Myers: Q3 Earnings Snapshot - The Washington Post
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance - MSN
Bristol-Myers Squibb Co. Q3 Profit Decreases, But Beats Estimates - Nasdaq
Bristol-Myers Squibb earnings beat by $0.30, revenue topped estimates - Investing.com South Africa
Bristol Raises Guidance on Demand for Eliquis, New Drugs - BNN Bloomberg
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs - CNBC
Bristol-Myers Squibb Q3 24 Earnings Conference Call At 8:00 AM ET - Nasdaq
Areas of interest - Bristol Myers Squibb
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Drugmakers urge appeals court to revive challenge to US drug price negotiation program - Reuters
Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated - MSN
Is Eli Lilly Stock a Buy? - The Motley Fool
Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is ‘Too Low’ - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day - MarketWatch
Should Bristol Myers Stock Be in Your Portfolio Pre-Q3 Earnings? - MSN
Will These 5 Big Drug Stocks Surpass Q3 Earnings Forecasts? - Yahoo Finance
UTSA announces partnership with Bristol Myers Squibb to advance pharmaceutical discoveries and development - The University of Texas at San Antonio
Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024 - StockTitan
Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - Simply Wall St
Psoriasis around the world - Bristol Myers Squibb
Allspring Global Investments Holdings LLC Has $11.12 Million Stake in Bristol-Myers Squibb (NYSE:BMY) - MarketBeat
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Second Circuit Weighs Whether Bristol-Myers Delayed Cancer Drug - Bloomberg Law
Citigroup downgrades Bristol-Myers Squibb to 'neutral' - XM
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
People and business resource groups - Bristol Myers Squibb
Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
December 6th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Bristol-Myers Squibb's SWOT analysis: stock faces challenges amid new approvals - Investing.com
Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring - GlobeNewswire
Spain CAR-T Cell Therapy Market Forecast to 2029, Featuring Strategic Profiles of Gilead Sciences, Novartis Int'l, Bristol Myers Squibb, AbbVie, AMGEN, Pfizer, Merck & Co, Johnson & Johnson - Yahoo Finance
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):